

CURRICULUM VITAE

SEMRA AYDIN, MD PhD

CURRENT POSITION:

Medical specialist in Internal Medicine, Hematology and Oncology, Department of Oncology, Hematology, Immunology and Rheumatology, University Hospital of Bonn, Bonn, Germany

ADDRESS:

Eifelstrasse 42, 53119 Bonn, Germany

E-mail: semra.aydin@ukbonn.de

semay74@hotmail.com

DATE OF BIRTH:

14.04.1974 in Bonn, Germany

NATIVE LANGUAGES:

German, Turkish, English, Italian

EDUCATION:

1993 – 2001

Medical School, University of Bonn, Germany

2001 – 2005

M.D. thesis „Long term results of coronary re-operations“, Department of Heart Surgery, University Hospital of Zurich, Switzerland, Prof. M. Turina

2003

Licence to practice medicine

CLINICAL WORKING EXPERIENCE

| | |
|----------------------|---|
| 2001-2005 | M.D. in the Centre for Internal Medicine: Departments of Hematology, Gastroenterology, Nephrology, Cardiology, Intensive care unit, Endocrinology, University of Duisburg-Essen Medical School, Essen, Germany. |
| 2009-2012 | M.D. at the West German Tumor Center: Department of Hematology, Prof. U. Dührsen, Department of Oncology, Prof. M. Schuler |
| 05/2012 | Specialisation in Internal Medicine, Haematology and Oncology in Essen, Germany |
| 2012-2020 | M.D. Department of Oncology and Hematology at the A.O.U. Citta della Salute e della Scienza di Torino, Italy, Dr. U. Vitolo |
| since September 2020 | Department of Oncology, Hematology, Immuno-oncology and Rheumatology, University Hospital of Bonn, Germany, Prof. P. Brossart |

SCIENTIFIC REFERENCES

| | |
|-------------------|--|
| 09/2005 - 09/2006 | ESMO-Fellowship in the Laboratory of Immunogenetics, Department of Genetics, Biology and Biochemistry, University of Torino, Italy |
| 10/2006 - 09/2007 | FIRMS-Fellowship (International Foundation for Research in Experimental Medicine) in the Laboratory of Immunogenetics, Department of Genetics, Biology and Biochemistry, University of Torino, Italy |
| 08/2007 - 07/2008 | Fellowship by the Dr. Werner Jackstädt-Stiftung, Wuppertal, Germany, for a stay in the Laboratory of Immunogenetics, Department of Genetics, Biology and Biochemistry, University of Torino, Italy |
| 2008 - 2012 | PhD in Biomedical Science and Human Oncology , direction of Advanced Techniques of Human Tumor Localisation. Thesis: "CD38 in CLL-from bench to bedside", Lab of Immunogenetics, Department of Genetics, Biology and Biochemistry, University of Torino, Italy, Prof. F. Malavasi, Prof. S. Deaglio |

2/2022-5/2022

FEM-HABIL- Uniklinikum Bonn, scientific grant including a visiting medical scientist, Hematology and Stem Cell Transplantation, EMSEY Hospital Istanbul, Turkey, Prof. S. B. Omay

TEACHING ACTIVITIES

1. 2012-2020: Teaching of medical students in Hematology and Stem Cell Transplantation, A.O.U. Citta della Salute e della Scienza di Torino, Italy, Dr. U. Vitolo
2. since 2020: Hematology, Oncology and Hematological Cytology at the Medical School of the University of Bonn, Bonn, Germany
3. since 2021: Teaching Modul Clinical Immunology II, University of Bonn, Bonn, Germany
4. since 2023: Teaching of medical students University of Bonn, Germany
5. since 2024: Teaching of dental medicine students, University of Bonn, Germany

MEMBERSHIPS

Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e.V. (DGHO- German Society of Hematology and Oncology)

Hematoloji Uzmanlik Dernegi (HUD- Turkish Society of Hematology Specialists)

Japanese Society of Hematology, since May 2022

Società Italiana di Ultrasonologia in Medicina e Biologia (SIUMB) (Italian Society of Ultrasound in Medicine and Biology)

Member of the Scientific Committee of the Italian Society of PNH (AIEPN) 2018-2020

PUBLISHED ORIGINAL FULL ARTICLES

1. **Aydin S**, Nückel H, Dührsen U. Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: a single-centre study of 20 patients. **Ann Hematol.** 2007 Apr;86(4):271-6.
2. D'Arena G, Tarnani M, Rumi C, Vaisitti T, **Aydin S**, De Filippi R, Perrone F, Pinto A, Chiusolo P, Deaglio S, Malavasi F, Laurenti L. Prognostic significance of combined analysis of ZAP-70 and CD38 in chronic lymphocytic leukemia. **Am J Hematol.** 2007 May 29;82(9):787-791.

3. Deaglio S, Vaisitti T*, **Aydin S***, Bergui L, D'Arena G, Bonello L, Omede' P, Scatolini M, Jaksic O, Chiorino G, Efremov D, and Malavasi F. CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential.*: equally contributed to the work. **Blood**. 2007 Dec1;110(12):4012-21.
4. **Aydin S**, Rossi D, Bergui L, D'Arena G, Ferrero E, Bonello L, Omede P, Novero D, Morabito F, Carbone A, Gaidano G, Malavasi F, Deaglio S. CD38 gene polymorphism and chronic lymphocytic leukemia: a role in transformation to Richter syndrome? **Blood**. 2008 Jun 15;111(12):5646-53.
5. Deaglio S, **Aydin S**, Grand MM, Vaisitti T, Bergui L, D'Arena G, Chiorino G, Malavasi F. CD38/CD31 interactions activate genetic pathways leading to proliferation and migration in chronic lymphocytic leukemia cells. **Mol Med**. 2010 March;16(3-4)87-9.
6. Vaisitti T, **Aydin S**, Rossi D, Cottino F, Bergui L, D'Arena G, Bonello L, Horenstein AL, Brennan P, Pepper C, Gaidano G, Malavasi F, Deaglio S. CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells. **Leukemia**. 2010 May;24(5):958-69.
7. **Aydin S**, Grabellus F, Eisele L, Mollmann M, Hanoun M, Ebeling P, Moritz T, Carpinteiro A, Nüchel H, Sak A, Göthert JR, Dührsen U, Dürig J. Investigating the role of CD38 and functionally related molecular risk factors in the CLL NOD/SCID xenograft model. **Eur J Hematol**. 2011 Jul;87(1):10-9.
8. Hanoun M, Eisele L, Suzuki M, Grealley JM, Hüttmann A, **Aydin S**, Scholtysik R, Klein-Hitpass L, Dührsen U, Dürig J. Epigenetic silencing of the circadian clock gene CRY1 is associated with an indolent course in chronic lymphocytic leukaemia. **PLoS One**.2012;7(3):e343-47.
9. Dellacasa CM, Busca A, Audisio E, Marmont F, Barbui AM, Falda M, De Rosa FG, Frairia C, Allione B, D'Ardia S, **Aydin S**, Pecoraro C, Manetta S, Vitolo U. Prevention of invasive fungal infections in patients with acute myeloid leukemia: results of a single centre retrospective observational study with the use of posaconazole versus conventional mould-active azoles. **J Chemother**. 2014 Oct;26(5):315-20.
10. Giaccone L, Audisio E, Bruno B, Maffini E, D'Ardia S, Caracciolo D, Ferrando F, Butera S, Brunello L, Frairia C, **Aydin S**, Nicolino B, Festuccia M, Crisà E, Bruna R, Passera R, Boccadoro M, Vitolo U, Busca A, Falda M, Marmont F. Role of chemotherapy and allografting in the treatment of acute lymphoblastic leukemia. **Clin Lymphoma Myeloma Leuk**. 2016 Feb;16(2):96-103.
11. Giaccone L, Festuccia M, Zallio F, Sorasio R, Brunello L, Maffini E, Dellacasa C, Passera R, Iovino G, **Aydin S**, Boccadoro M, Vitolo U, Mordini N, Pini M, Busca A, Bruno B. Long-term follow-up of allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma. **Bone Marrow Transplant**. 2017 Aug;52(8):1208-1211.
12. Frairia C, **Aydin S**, Audisio E, Riera L, Aliberti S, Allione B, Busca A, D'Ardia S, Dellacasa CM, Demurtas A, Evangelista A, Ciccone G, Francia di Celle P, Nicolino B, Stacchini A, Marmont F, Vitolo U. Post-remissional and pre-transplant role of minimal residual disease detected by WT1 in acute myeloid leukemia: A retrospective cohort study. **Leuk Res**. 2017 Oct;61:10-17.

13. Busca A, Passera R, Maffini E, Festuccia M, Brunello L, Dellacasa CM, **Aydin S**, Frairia C, Manetta S, Butera S, Iovino G, Giaccone L, Sorrow M, Storb R, De Rosa FG, Bruno B. Hematopoietic cell transplantation comorbidity index and risk of developing invasive fungal infections after allografting. **Bone Marrow Transplant**. 2018 Oct;53(10):1304-1310.
14. Brunello L, Passera R, Dellacasa C, Giaccone L, Audisio E, Ferrero D, D'Ardia S, Allione B, **Aydin S**, Festuccia M, Lia G, Crisà E, Maffini E, Butera S, Busca A, Bruno B. Haplo-identical allografting with post-transplant Cyclophosphamide in high-risk patients. **Ann Hematol**. 2018 Nov;97(11):2205-2215.
15. **Aydin S**, Dellacasa C, Manetta S, Giaccone L, Godio L, Iovino G, Bruno B, Busca A. Rescue treatment with Eltrombopag in refractory cytopenias after allogeneic stem cell transplantation. **Ther Adv Hematol**. 2020 Oct 20;11:2040620720961910.
16. Barcellini W, Fattizzo B, Giannotta JA, Quattrocchi L, **Aydin S**, Barone F, Carbone C, Pomponi F, Metafuni E, Beggiato E, Sica S, Di Bona E, Lanza F, Notaro R, Iori AP. COVID-19 in patients with paroxysmal nocturnal haemoglobinuria: an Italian multicentre study. **Br J Haematol**. 2021 Sep;194(5):854-856.
17. Yakymiv Y, Augeri S, Bracci C, Marchisio S, **Aydin S**, D'Ardia S, Massaia M, Ferrero E, Ortolan E, Funaro A. CD157 signaling promotes survival of acute myeloid leukemia cells and modulates sensitivity to cytarabine through regulation of anti-apoptotic Mcl-1. **Sci Rep**. 2021 Oct 27;11(1):21230.
18. **Aydin S**, Passera R, Scaldaferrì M, Dellacasa C, Poggiu M, Cattell F, Zallio F, Brunello L, Giaccone L, Dogliotti I, Busca A. Sorafenib maintenance after hematopoietic stem cell transplantation improves outcome of FLT3-ITD-mutated acute myeloid leukemia. **Int J Hematol**. Accepted for publication 27.7.2022.
19. **Aydin S**, Passera R, Cerrano M, Gai V, D'Ardia S, Iovino G, Dellacasa CM, Audisio E, Busca A. Combining the HCT-CI, G8, and AML-Score for Fitness Evaluation of Elderly Patients with Acute Myeloid Leukemia: A Single Center Analysis. **Cancers (Basel)**. 2023 Feb 4;15(4):1002.
20. Urbino I, Frairia C, Busca A, Corcione S, D'Ardia S, Dellacasa CM, Gai V, Secreto C, Freilone R, De Rosa FG, **Aydin S**, Ciccone G, Rosato R, Cerrano M, Audisio E. Levofloxacin Prophylaxis Versus no Prophylaxis in Acute Myeloid Leukemia During Post-Induction Aplasia: a Single Center Study. **Mediterr J Hematol Infect Dis**. 2023 Mar 1;15(1):e2023022.

PUBLISHED REVIEW ARTICLES

1. Deaglio S, Vaisitti T, **Aydin S**, Ferrero E, Malavasi F. In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia. **Blood**. 2006 Aug 15;108(4):1135-44.

2. Malavasi F, Deaglio S, Ferrero E, Funaro A, Sancho J, Ausiello CM, Ortolan E, Vaisitti T, Zubiaur M, Fedele G, **Aydin S**, Tibaldi EV, Durelli I, Lusso R, Cozno F, Horenstein AL. CD38 and CD157 as receptors of the immune system: a bridge between innate and adaptive immunity. **Mol Med**. 2006 Nov-Dec;12(11-12):334-41.
3. Deaglio S, **Aydin S**, Vaisitti T, Bergui L, Malavasi F. CD38 at the junction between prognostic marker and therapeutic target. **Trends Mol Med**. 2008 May;14(5):210-8. IF: 12.8
4. Malavasi F, Deaglio S, Funaro A, Ferrero E, Horenstein AL, Ortolan E, Vaisitti T, **Aydin S**. Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. *Physiol Rev*. 2008 Jul;88(3):841-86. IF:
5. Urbino I, Secreto C, Olivi M, Apolito V, D'Ardia S, Frairia C, Giai V, **Aydin S**, Freilone R, Dellacasa C, Giaccone L, Ferrero D, Audisio E, Busca A, Cerrano M. Evolving Therapeutic approaches for older patients with acute myeloid leukemia in 2021. **Cancers** (Basel). 2021 Oct 11;13(20):5075.

PUBLISHED CASE REPORTS

1. Wiesweg M, **Aydin S**, Koeninger A, Stein A, Schara U, van Roye C, Hense J, Welt A, Schuler M. Administration of Gemcitabine for metastatic adenocarcinoma during pregnancy: A case report and review of the literature. **AJPRep**. 2014 May; 4(1): 17-22.
2. Dellacasa CM, D'Ardia S, Allione B, **Aydin S**, Tassi V, Francisci T, Pecoraro C, Busca A. Efficacy of plasmapheresis for the treatment of pure red cell aplasia after allogeneic stem cell transplantation. **Transfusion**. 2015 Dec;55(12):2979-82.
3. Castellino A, Guidi S, Dellacasa CM, Gozzini A, Donnini I, Nozzoli C, Manetta S, **Aydin S**, Giaccone L, Festuccia M, Brunello L, Maffini E, Bruno B, David E, Busca A. Late-Onset Hepatic Venous Occlusive Disease after Allografting: Report of Two Cases with Atypical Clinical Features Successfully Treated with Defibrotide. **Mediterr J Hematol Infect Dis**. 2018 Jan 1;10(1):e2018001.
4. Busca A, Dellacasa C, Giaccone L, Manetta S, Biale L, Godio L, **Aydin S**, Festuccia M, Brunello L, Bruno B. Eltrombopag for the Treatment of Refractory Pure RBC Aplasia after Major ABO Incompatible Hematopoietic Stem Cell Transplantation. **Biol Blood Marrow Transplant**. 2018 Aug;24(8):1765-1770.

BOOK CHAPTER

1. Giovanni D'Arena, Tiziana Vaisitti, **Semra Aydin** and Silvia Deaglio. CD38 Expression in B-Cell Chronic Lymphocytic Leukemia: What Have We Learned? In: Chronic Lymphocytic Leukemia Research Focus, Chapter 4. ISBN: 978-1-60021-526-1, Editor: Chadi Nabhan, ©2007 Nova Science Publishers, Inc.

ORAL PRESENTATIONS AT NATIONAL AND INTERNATIONAL MEETINGS

1. 4th international CLL Workshop - Update on Biology and Therapy of Chronic Lymphocytic Leukemia 2008,17. Mai, Salzburg, Österreich: Lecture on 'CD38 and ZAP-70 crosstalk' (on behalf of: Prof. Dr. Silvia Deaglio)
2. 33rd ESMO Congress Stockholm 2008, 12.-16. September, Stockholm, Schweden: **Aydin S**, Vaisitti T, Bergui L, Omedé P, Bonello L, D'Arena G, Malavasi F, Deaglio S. CXCL12-mediated chemotaxis of chronic lymphocytic leukemia is regulated by CD38 and Zap-70.
3. Winterseminar der Medizinischen Fakultät der Universität Duisburg-Essen 2009, 12.-14. Februar, Pichl, Österreich. **Aydin S**. CD38 tunes CXCL12 mediated homing of CLL cells: early evidence for therapeutic applications?
4. Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie (DGHO) Jahrestagung 2010, 1.-5. Oktober, Berlin, Deutschland. **Aydin S**, Grabellus F, Ebeling P, Möllmann M, Lewin E, Nüchel H, Dürig J. The impact of CD38 in the CLL NOD/SCID xenograft model. *Onkologie* 2010;33(6):1–294.V 673.
5. XIII Eurasian Hematology Oncology Congress (EHOC), 2022, 5.-8. Oct. **Aydin S**. How we(II) treat PNH? *Hematology, Transfusion and Cell Therapy*; 2022; 44(1), S37
6. SOHO 2024 Turkey, S. 2027, 27.-28. April: How to Sequence Immunotherapies CAR T First (Claudio Cerhione) vs Bispecific (Semra **Aydin**)
7. XV Eurasian Hematology Oncology Congress (EHOC), 2024, 28.-30.4. **Aydin S**. PNH.
8. 10. Batı Karadeniz Hematoloji Günleri (BKHG- West Blacksee Hematology Days 2024, 17.-19.5. **Aydin S**. PNH vakalar tabanlı yaklaşım (PNH cases oriented approach).